Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Gout Drug Shown to Benefit Diabetes Patients at Risk of Heart Disease

Published: Wednesday, September 04, 2013
Last Updated: Wednesday, September 04, 2013
Bookmark and Share
New research has led to the possibility of using an old drug to help prevent the biggest cause of death in Type II diabetes patients.

Allopurinol, an inexpensive drug used to prevent gout for more than 50 years, has been shown to reduce thickening of the heart muscle wall, known as Left Ventricular Hypertrophy (LVH), in diabetes patients. Reducing thickening is known to help reduce the risk of future cardiovascular events and, as heart disease and stroke account for 65 per cent of all fatalities in people with diabetes, the findings offer the possibility of improving the life expectancy of patients.
 
The senior corresponding author on the study, Dr Jacob George from the University’s Division of Cardiovascular & Diabetes Medicine says that this follows on from previous studies at Dundee that have shown that allopurinol has benefits for patients with heart failure, angina and previous stroke.
 
“Cardiovascular disease is the single biggest cause of death in diabetic patients,” said Dr George. “Diabetics’ cardiovascular risk is significantly higher than non-diabetics. In particular, large trials have previously shown us that patients with left ventricular hypertrophy are at much higher risk and so it should follow that if we reduce LVH we will reduce mortality rates.
 
“Previously, our group have looked at patients with coronary artery disease and how allopurinol helps them, but this is the first time we have looked specifically at people with Type II diabetes who have heart muscle thickening.
 
“There may be different reasons for patients with coronary heart disease and those with diabetes experiencing left ventricular hypertrophy and although we had good reason to suppose that allopurinol should help to reduce thickening in this second group, it had never been proven before.
 
“It was very important to show that allopurinol was able to reduce LVH in diabetics as well as non-diabetic coronary artery disease patients. As obesity becomes more of an issue in the UK and diabetes becomes more prevalent, this treatment could become an important weapon in improving the cardiovascular outcome in diabetic patients.”
 
Dr George and his colleagues looked at a sample group of 66 Type II diabetes patients, half of whom who were given allopurinol and half a placebo for nine months. The results showed that the thickness of the heart muscle wall, measured by cardiac MRI, was significantly reduced in the group who took allopurinol.
 
It is believed that allopurinol reduces oxidative stress, the process that leads to the production of damaging free radicals that cause thickening of the left ventricle of the heart, while also improving blood vessel health. This means the blood vessels will provide less resistance against the pumping of the heart and such resistance has been shown to cause LVH.
 
The research, funded by the charity Diabetes UK, is also interesting in that it shows allopurinol does not affect blood pressure, unlike other drugs currently used to reduce LVH.
 
Dr George continued, “The most common reason for developing LVH is high blood pressure but our patients were very well controlled with optimal treatments currently available for patients and despite that still experienced thickening. This might be down to oxidative stress molecules, and there is evidence that diabetes patients experience higher levels of this that the non-diabetic population.
 
“If a larger-scale study backs up these findings then there is reason to be excited about the potential for using allopurinol as a therapy to reduce cardiovascular events in patients with Type II diabetes. It has been on the market for decades so is cheap and safe and our research suggests it is a way of treating LVH without lowering blood pressure.
 
“This is another piece of the large jigsaw we’ve been putting together in Dundee for over the last 20 years. We have shown that allopurinol has potential in heart failure, coronary artery disease, stroke and now diabetes patients. We are building a body of evidence that will allow us to determine whether putting patients on high doses of allopurinol is a realistic way of significantly reducing cardiovascular mortality.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!